← All stories
Tech
AstraZeneca keeps blue-chip growth anchored in medicines, pipeline depth and global scale
Highlights A broad portfolio reduces dependence on any single medicine but does not remove pipeline risk. Oncology and specialty therapies remain central to the company's growth ambition. Clinical milestones, commercial launches and patent…
Covered by 1 outlet
All coverage · 1 article